- Company
- “RSA expansion, a foundation to expedite new drug listing"
- by Eo, Yun-Ho Jan 10, 2020 06:26am
- A ‘new drug’ holds the foremost value of the pharmaceutical industry. And global pharmaceutical companies’ eyes are currently fixated on the ‘adequate value of new drug’ than ever before. As the era of high-cost drug has come, government and pharmaceutical industry’s gap in views of drug pricing has never been so apart. Korea Research-
- Company
- The controversy of Eliquis' fluctuating price
- by Jung, Hye-Jin Jan 10, 2020 06:25am
- The price of Eliquis, an anticoagulant drug, Apixaban, has fluctuated several times. Wholesalers and pharmacies dealing with dispensing and distribution are also confused. In particular, as the most recent provisional disposal application that Korea BMS applied for was accepted earlier than expected, some pharmacies and wholesalers had to
- Company
- Valsartan's third payment deadline has expired
- by Chon, Seung-Hyun Jan 10, 2020 06:24am
- The third payment deadline for the Valsartan damages claim urged by health authorities has ended. Most of the companies that did not pay the compensation were refused to pay. The health authorities say they will continue to incentivize payments, but a lawsuit filed by pharmaceutical companies will conclude the legitimacy of government action.
- Company
- PPC signs co-marketing partnership with Biosuntek
- by Eo, Yun-Ho Jan 10, 2020 06:23am
- PPC Korea and Biosuntek Laboratory (“Biosuntek”) have agreed to co-market pharmaceutical clinical development. PPC Korea, a contract research organization (CRO) providing service in Asian region, has invested in a bioequivalence test analyst institute, Biosuntek Laboratory and signed a strategic partnership agreement on Jan. 8. The
- Company
- Big Pharmas butting heads over Faslodex combination
- by Eo, Yun-Ho Jan 9, 2020 09:06am
- Three investigational drugs are busy preparing for applying reimbursement on a combination therapy with Faslodex. The competing three investigational drugs are cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor treatment&8212;Pfzier’s Ibrance (palbociclib), Lilly’s Verzenio (abemaciclib), and Novartis’ Kisqali (ribociclib). The
- Company
- Yuyu Pharma rewards stock grant valued at KRW 500 million
- by Lee, Seok-Jun Jan 9, 2020 06:25am
- This year again, Yuyu Pharma granted the company’s stock to its employee as an incentive award. Since July 2017, the pharmaceutical company has been granting shares of the company stock to selected top employees, biannually. Employees rewarded with the stock grant can immediately liquidate it as they directly receive the share the company o
- Company
- Near miss, tension in the Middle East
- by Kim, Jin-Gu Jan 8, 2020 06:18am
- Amid rising military tensions between the United States and Iran, there is also concern about bad influence on trade between Korea and Iran. In the case of drugs, exports have already been blocked since last year. There is also concern that the resumption of exports will be postponed indefinitely. According to the Korea Customs Service's i
- Company
- Tension on impurity diabetic drugs is for a month
- by Chon, Seung-Hyun Jan 8, 2020 06:17am
- It's been a month since concerns of impurity Metformin were triggered overseas, but there are still no clear conclusions. Expectations are raised in the pharmaceutical industry that there is no recovery country other than Singapore and that it can only be a surprise. However, there is still a lot of tension that if there is a recovery fr
- Company
- Pfizer Korea is looking for a new office
- by Kim, Jin-Gu Jan 7, 2020 06:29am
- Pfizer Korea is pursuing the sale of its Myeong-dong office, which has stayed for the past 13 years. Location of new office is planning Yeouido, Jamsil or Pangyo. According to the pharmaceutical industry on the 6th, Pfizer Korea is considering the sale of its office and relocation of its office. Currently, Pfizer Korea is located at 110
- Company
- SNU professor investigates new anti-cholesterol medicine
- by Eo, Yun-Ho Jan 7, 2020 06:29am
- Researchers in Korea are onto developing a next generation anti-cholesterol medicine. Pharmaceutical industry reported on Jan. 7, a team of Seoul National University researchers led by Professor Kim Hyo-soo is preparing a Phase 1 clinical study on candidate medicine inhibiting cyclase-associated protein 1 (CAP1). Previously, Seoul N
